Journal
MOLECULAR CANCER RESEARCH
Volume 19, Issue 12, Pages 1980-1991Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1541-7786.MCR-21-0161
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81802738]
Ask authors/readers for more resources
DCLK1-S expression is significantly increased in human esophageal squamous cell carcinoma (ESCC) tissues and is associated with malignant progression and poor prognosis. Functional studies showed that DCLK1-S plays a role in promoting ESCC cell proliferation, migration, and invasion, potentially through the MAPK/ERK/MMP2 pathway. These findings suggest that DCLK1-S may serve as a biomarker or therapeutic target for improving outcomes in patients with ESCC.
Cancer stem cell (CSC) marker doublecortin-like kinase 1 (DCLK1) contributes greatly to the malignancy of gastrointestinal cancers, and DCLK1-targeted agents have potential therapeutic value. However, the molecular pathways regulated by DCLK1-S (DCLK1 isoform 4), a shortened splice variant of DCLK1, still remain obscure. Here we found that the expression of DCLK1-S is significantly increased in human esophageal squamous cell carcinoma (ESCC) tissues and associated with malignant progression and poor prognosis. Functional studies indicated that silencing total of DCLK1 mediated by CRISPR/Cas9 inhibited ESCC cell proliferation, migration, and invasion. Conversely, these changes were largely reversed after DCLK1-S rescue or overexpression. More importantly, DCLK1-S significantly enhanced primary tumor formation and metastatic lung colonization in vivo. The Cancer Genome Atlas database and molecular analysis showed that DCLK1-S was closely related to the epithelial-mesenchymal transition (EMT) process in patients with ESCC. Further RNA sequencing and Kyoto Encyclopedia of Genes and Genomes analysis demonstrated that MAPK signaling pathway was significantly enriched. Our in vitro study proclaimed that DCLK1-S induced MMP2 expression in ESCC cells via MAPK/ERK signaling, leading to the activation of EMT. In addition, administration of ERK1/2 blocker SCH772984 attenuated the proliferative and migratory phenotype induced by DCLK1-S. In conclusion, these findings suggest that DCLK1-S may be a key molecule in MAPK/ERK/MMP2 pathway-mediated progression of ESCC, and that it has potential as a biomarker or therapeutic target to improve outcomes in patients with ESCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available